← All Inmune Bio, INC filings

Inmune Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
INMB
Inmune Bio, INC
10-K: INmune Bio Reports Full Year 2024 Results, CORDStrom Advances Towards BLA Filing
INmune Bio's 2024 annual report highlights progress in clinical trials, particularly for CORDStrom in RDEB, while acknowledging ongoing financial challenges and efforts to secure additional funding.
NASDAQ
INMB
Inmune Bio, INC
10-K/A: INmune Bio Files Amended 10-K to Include Omitted Information
INmune Bio Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
INMB
Inmune Bio, INC
10-K: INmune Bio Inc. Files 10-K Annual Report, Outlines Progress in Immunotherapy Development
INmune Bio Inc. released its 10-K annual report, detailing its financial status and advancements in its immunotherapy programs targeting cancer, Alzheimer's disease, and treatment-resistant depression.